cells, which are also highly exposed to environmental stress, cardiac myocytes cannot be easily sloughed and replaced when damaged. Accordingly, myocardial cells are equipped with a number of powerful damage-protective strategies, including oxidant buffers and survival factors that ward off premature cell death decisions in the face of temporary challenges. When these protective mechanisms are impaired, the heart becomes more vulnerable to a range of toxic and oxidative stresses.
Neuregulin-1 is part of a family of naturally occurring membrane-anchored or secreted glycopeptides related to epidermal growth factor (EGF) that have multiple effects on the nervous and cardioldelim vascular systems (1, 2) . Neuregulin was originally thought to be a ligand for the EGF receptor (EGFR) Neu (HER2, ErbB2), and its name reflects that history; it is now known to bind 2 other EGFRs, ErbB3 and ErbB4. Neuregulin-1 binding leads to the preferential formation of ErbB2-ErbB4 heterodimers, activation of ErbB receptor tyrosine kinase activity, and downstream signaling through phosphotidyl inositol 3-kinase and Akt.
Neuregulin is secreted by epithelial cells that lie in close proximity to myocytes, as in endocardial and microvascular epithelia, and exerts paracrine effects on myocytes that pattern normal cardiac development, and control myocyte proliferation and differentiation (3). Genetic deletion of neuregulin or its receptor ErbB4 confer similar defects in heart development and lead to early embryonic lethality (2).
In the adult heart, neuregulin is activated by stress (4) and has a number of actions that are potentially favorable to cardiac function and repair after injury.
Notably, neuregulin has been shown to promote generation of new myocytes during development, and for a short window of time after birth in injury models (5-7). Application of neuregulin to myocytes from older animals has little effect on proliferation, possibly due to the downregulation of both ErbB2 and Erb4 on these cells after birth (5, 6, 8) . Neuregulin can also promote the emergence of mature cardiomyocytes from progenitor cells (9-11), improve contractility and glucose uptake (12) , and favorably alter the balance of adrenergic and cholinergic tone in the myocardium (1) . Importantly, it appears to protect against cell loss during oxidative stress in both small and large animal models (13) (14) (15) . Florida. Dr. Bishopric has reported that she has no relationships relevant to the contents of this paper to disclose. There is a relative dearth of truly novel approaches to heart failure, especially treatments that target the myocyte itself rather than its hemodynamic demands.
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Hence, the attractiveness of a therapy that may act directly on myocyte cell fate decisions, similar to the recent enthusiasm for regenerative therapies in heart failure. Especially given the desperate lack of alternatives for this crippling and ultimately fatal disease and the many years of dedicated effort by this research team, the opportunities for positive bias are many.
There are significant weaknesses to the current study.
The small number of subjects, the even smaller number of patients in the responding group, the weakness 
